Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
The Motley Fool July 27, 2004 Brian Gorman	Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans.
The Motley Fool July 30, 2009 Brian Orelli	A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money.
The Motley Fool February 25, 2009 Brian Orelli	The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers.
The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
The Motley Fool February 16, 2005 Brian Gorman	Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies?
The Motley Fool November 2, 2005 Brian Gorman	Medco's Bitter Pill The pharma benefits manager has hit a speed bump but looks well-positioned for the long haul. Investors, take note.
The Motley Fool April 19, 2011 Bryan White	Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies.
The Motley Fool November 3, 2010 Brian Orelli	A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it.
The Motley Fool October 24, 2006 Brian Gorman	Medco's Fringe Benefits Recent developments will present some challenges, but Medco remains a solid long-term investment.
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool October 29, 2009 Brian Orelli	Expressing Itself Nicely A nice quarter for Express Scripts.
The Motley Fool April 30, 2008 Brian Orelli	Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs.
The Motley Fool June 30, 2011 David Williamson	Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split.
The Motley Fool February 14, 2005 Brian Gorman	GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision.
The Motley Fool April 13, 2009 Brian Orelli	Prescriptions for Acquisitions Express Scripts announces that it is buying WellPoint's NextRx pharmaceutical benefit management subsidiaries for almost $4.7 billion.
The Motley Fool July 25, 2011 Brian Orelli	Express-Medco: Just What the Doctor Prescribed In perhaps the most obviously beneficial merger ever, Express Scripts announced its plan to buy Medco Health Solutions for $29.1 billion.
The Motley Fool April 27, 2005 Brian Gorman	Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back.
The Motley Fool August 16, 2010 Brian Orelli	The Fine Line Between Saving Money and Making It Medco's trying to walk it.
BusinessWeek March 7, 2005 Amy Barrett	A Drug Company On Growth Hormones By adding Accredo to its portfolio, Medco gains a strong presence in the area of specialty drugs. Investors sent Medco's stock down slightly on news of the deal. But they give company chief David B. Snow Jr. credit for putting Medco in a position to capitalize on new opportunities.
The Motley Fool August 1, 2008 Brian Orelli	Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line.
The Motley Fool March 6, 2009 Brian Orelli	Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now?
The Motley Fool January 3, 2012 Shubh Datta	Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts.
The Motley Fool October 6, 2011 Dan Caplinger	Has Medco Health Solutions Become the Perfect Stock? A lot has happened in the pharmacy benefits management space since we looked at Medco last year.
The Motley Fool March 22, 2010 Dave Mock	A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst.
The Motley Fool January 13, 2009 Dayana Yochim	Fiscal Fitness '09: 6 Ways to Score Cheap(er) Drugs Save more than $200 on prescriptions.
CFO March 1, 2012 David McCann	Companies May Win This Drug War The conflict between Express Scripts and Walgreen just might lead to lower drug-benefit costs for companies.
The Motley Fool September 27, 2006 Michael P. Cecil	A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales.
The Motley Fool August 1, 2006 Selena Maranjian	Prescription for Prescription Bargains Did you know that your medications might be cheaper around the corner? Another way to offset your net expenses on medications is to make some money on drugs -- by investing in drug-related firms.
Managed Care October 2003	Medco Health Solutions tops consumer survey The 2003 WilsonRx Survey reports that patients have identified Medco Health Solutions as the top pharmacy benefit manager for the third year in a row.
PC Magazine August 19, 2003 Alan Cohen	Online Prescriptions With $1.4 billion in sales last year, Merck subsidiary Medco Health online is doing something right.
The Motley Fool November 8, 2006 Michael P. Cecil	CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm.
The Motley Fool August 15, 2007 Mary Dalrymple	Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money.
Managed Care March 2006	Study: No Need To Burden Consumers To Cut Drug Bill A study by Express Scripts shows that changing the prescription benefit copayments can reduce costs by encouraging more use of generic drugs. All without shifting costs to consumers.
The Motley Fool February 4, 2010 Brian Orelli	Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct.
The Motley Fool June 24, 2011 Shubh Datta	A Big Question Looms for Walgreen Strong quarterly results enable the company to maintain its annual outlook, but a breakup costs dearly in the short term.
The Motley Fool May 4, 2011 Jason Knapp	Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will.
The Motley Fool September 21, 2006 Nathan Parmelee	Wal-Mart Goes Generic The supposed most terrible retailer of all is doing a very good thing with generic drug sales. The program will, of course, benefit Wal-Mart by creating additional traffic to its stores. This move could change the game for a number of retailers over the next few years.
The Motley Fool November 2, 2006 Ryan Fuhrmann	CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note.
The Motley Fool October 8, 2011 Shubh Datta	Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide.
The Motley Fool February 28, 2005 Brian Gorman	Medco Covers Its Bases Medco's purchase of Accredo is a nod to future growth in biotech drug spending.
The Motley Fool October 28, 2010	Our Top Stock Idea Our investing community's latest prime pick -- Medco Health Solutions.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool September 21, 2006 Vitaliy Katsenelson	Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them.
The Motley Fool November 9, 2005 Brian Gorman	Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company.
The Motley Fool September 26, 2006 Ryan Fuhrmann	Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?
Managed Care July 2005	Cost being equal, consumers prefer older drugs Seven out of 10 consumers would prefer a drug that had been on the market for 10 years or more, compared to a newer drug, even if the copayments were equal. This could be a sign that consumers are more inclined to start using generic medications.
The Motley Fool October 2, 2011 Shubh Datta	Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment?
Managed Care October 2005	Health Plans Pay Less When PBM Owns Mail-Order Pharmacy The ongoing debate on whether health plans pay more for drugs when using a mail-order pharmacy owned by a pharmacy benefits manager (PBM) or when the mail-order pharmacy is not owned by a PBM may be closer to resolution.
The Motley Fool January 3, 2006 Stephen D. Simpson	Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.